• FDA refuses to review Moderna's mRNA influenza vaccine application.
• The rejection is due to inappropriate comparison with other vaccines.
• Moderna maintains its vaccine shows better efficacy than current options.
• No safety or efficacy concerns were cited by the FDA.
• The decision comes amid a rollback of longstanding vaccination guidelines in the US.

The United States Food and Drug Administration (FDA) has declined to review Moderna's application for its mRNA influenza vaccine, mRNA-1010, based on the company's choice of comparator in its study. The FDA stated that the comparison to an existing licensed flu vaccine did not meet the necessary standards, as it lacked adequate and well-controlled data. Moderna reported that the refusal-to-file letter did not cite any safety or efficacy concerns, a point underscored by its CEO, Stephane Bancel, who expressed confusion over the decision's inconsistency with previous communications from the FDA, according to Channel News Asia, AA, and Al Jazeera.

In its rejection letter, the FDA emphasized that Moderna's analysis did not incorporate what it termed the "best-available standard of care" for its trials. This marks a significant decision as it comes amidst a backdrop of shifting vaccination guidelines in the United States, causing concern among public health experts regarding the transparency and scientific basis of recent federal actions. Moderna's application had initially included data showing that its influenza vaccine was reportedly 26.6% more effective than an annual flu shot from GlaxoSmithKline, indicating potential for enhanced efficacy that is now stalled due to the regulatory decision, according to Channel News Asia and Al Jazeera.

Following the FDA's refusal, Moderna has sought a Type A meeting to clarify and discuss the pathway forward from here. The concerns expressed by health experts reveal a deeper unease about potential political influences impacting the FDA’s regulatory decisions, especially as the organization's recent actions have left industry stakeholders questioning the meritocratic nature of these outcomes. Reports suggest that career scientists within the FDA initially supported the review process, yet the final decision appeared to be dictated from higher authority, raising alarms over the credibility of the agency's current leadership, noted AA and Al Jazeera.

Financially, this rejection poses a considerable challenge to Moderna's business, which has been struggling with dwindling vaccine sales since the peak COVID-19 vaccination era. The FDA's decision could impede the company's goal of achieving cash flow break-even by 2028, as analysts indicate that the decline in vaccine approval chances can substantially derail financial projections. In recent market movements, Moderna saw shares drop significantly in the wake of the news but appear to have slightly recovered, although still low compared to previous highs, according to Channel News Asia and Al Jazeera.